As of 11 August 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy. The HTA Council hereby releases its preliminary recommendation on the continue reading : HTA Council Preliminary Recommendation on trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy
HTA Council Final Recommendation on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 11 June 2026Date of notification to HTAC on the SOH decision: 30 July 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia as an adjunct to maximally-tolerated statin therapy through Department of Health (DOH) continue reading : HTA Council Final Recommendation on ezetimibe [10 mg tablet] for the treatment of hyperlipidemia (with Secretary of Health Decision)
[FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Digital Health Technologies (DHT)
Published on 08 July 2026 This is to update all our stakeholders that the Health Technology Assessment (HTA) Council has completed the Philippine HTA Methods Guide for Assessing Digital Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Methods Guides across different health technologies. This new methods guide shall complement continue reading : [FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Digital Health Technologies (DHT)
[FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Preventive and Promotive Health (PPH) Technologies
Published on 08 July 2026 This is to update all our stakeholders that the Health Technology Assessment (HTA) Council has completed the Philippine HTA Methods Guide for Assessing Preventive and Promotive Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Methods Guides across different health technologies. This new methods guide continue reading : [FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Preventive and Promotive Health (PPH) Technologies
HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
As of 08 July 2026, the HTA Council has completed the evidence appraisal on the assessment of ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for the treatment of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) in adult hospitalized patients ≥18 years. As a continue reading : HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)